Studies & Results
TRIO019
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
View FDA Study View EU Study
Presentations
San Antonio Breast Cancer Symposium, 2015
Hurvitz SA, Andre F, Jiang Z, et al
Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1.
ASCO Annual Meeting, 2015
Slamon DJ, Hurvitz SA, Chen D, et al
Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.
ASCO Annual Meeting, 2012
Hurvitz S, Andre F, Burris HA, et al
BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).
Publications
Hurvitz SA, Andre F, Jiang Z, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Lancet Oncol 16:816–829, 2015
von Minckwitz G: A step towards a HER2-positive breast cancer super family.
Lancet Oncol 16:745–746, 2015
Toi M, Shao Z, Hurvitz S, et al: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
BreastCancerResearch (2017) 19:47
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
San Antonio Breast Cancer Symposium, 2015
Hurvitz SA, Andre F, Jiang Z, et al
Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1.
ASCO Annual Meeting, 2015
Slamon DJ, Hurvitz SA, Chen D, et al
Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.
ASCO Annual Meeting, 2012
Hurvitz S, Andre F, Burris HA, et al
BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).
Publications
Hurvitz SA, Andre F, Jiang Z, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16:816–829, 2015
von Minckwitz G: A step towards a HER2-positive breast cancer super family. Lancet Oncol 16:745–746, 2015
Toi M, Shao Z, Hurvitz S, et al: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1 BreastCancerResearch (2017) 19:47
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org